Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

66.79 -0.24 (-0.36%)
Streaming Delayed Price Updated: 11:43 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by... 
Via Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs. 
Via Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Expert Ratings for Gilead Sciences
Via Benzinga
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
3 Stocks Retirees Should Absolutely Love
These stocks offer solid income plus more. 
Via The Motley Fool
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility  
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives
DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing... 
Via Talk Markets
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future. 
Via The Motley Fool
The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023
The market is soaring, but there is still time to buy these seven undervalued Nasdaq stocks before they head higher. 
Via InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
It helps to offer products everyone needs. 
Via The Motley Fool
This Is What Whales Are Betting On Gilead Sciences
Via Benzinga
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Read the latest report on NanoViricides here. 
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
These stocks are built to withstand a bear market. 
Via The Motley Fool
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,  
Via Benzinga
7 Tech Stocks to Watch on July 14
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
Some businesses never go out of style. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.